A soft cold and flu season was the dominant Q1 narrative for Reckitt. Core LFL net revenue growth came in at 1.3%, but excluding the seasonal OTC drag, the underlying figure was 3.1% (per the Reckitt Q1 2026 trading update and Investing.com earnings call coverage).
The regional split tells the structural story. Emerging Markets grew 7.6% LFL to £1,087m, powered by Dettol, Gaviscon, and vitamins, minerals and supplements. Europe was weaker, citing low seasonal incidence and broader category softness. Mead Johnson Nutrition declined 2.7% LFL to £531m, with volume down 6.8% offset by price/mix up 4.1%.
Management reaffirmed FY 2026 guidance: Core LFL net revenue growth of 4 to 5%. The reset thesis hinges on the cold and flu season normalising in H2, supported by innovation including Mucinex 12-hour Cold and Fever shipping in North America from June 2026.
The £1 billion share buyback programme is on schedule, with £669m completed by 17 April 2026.
For commercial teams in OTC and consumer health, the read is that 2026 brand-investment cycles are running on a mean-reversion assumption for seasonal demand. If H2 cold and flu incidence stays soft, the recovery thesis weakens and Reckitt may need to revisit guidance at the half-year. The Mead Johnson trajectory is the second watch item, particularly given the recent strategic-review noise around the unit.